DERM Dermira, Inc.
Dermira, Inc. (DERM) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.02 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.1% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Dermira, Inc.
Dermira Inc is a biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients.
Sector
Healthcare
Industry
Drug Manufacturers/Other
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.